Short Interest in Pasithea Therapeutics Corp. (NASDAQ:KTTA) Declines By 34.5%

31 Jan 2026, 19:42 by Doug Wharley · The Cerbat Gem

Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 366,534 shares, a decrease of 34.5% from the December 31st total of 559,624 shares. Based on an average trading volume of 283,614 shares, the days-to-cover ratio is currently 1.3 days. Approximately 1.6% of the company’s stock are sold short. Approximately 1.6% of the company’s stock are sold short. Based on an average trading volume of 283,614 shares, the days-to-cover ratio is currently 1.3 days.

Pasithea Therapeutics Trading Up 0.1%

KTTA traded up $0.00 during trading on Friday, reaching $0.86. 131,088 shares of the company’s stock were exchanged, compared to its average volume of 198,699. Pasithea Therapeutics has a one year low of $0.28 and a one year high of $3.85. The firm has a fifty day moving average price of $1.04 and a two-hundred day moving average price of $0.84. The stock has a market capitalization of $19.88 million, a PE ratio of -0.17 and a beta of 0.22.

Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.41) EPS for the quarter.

Wall Street Analysts Forecast Growth

KTTA has been the subject of several analyst reports. Wall Street Zen upgraded Pasithea Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, January 18th. Zacks Research raised shares of Pasithea Therapeutics to a “hold” rating in a research note on Tuesday, December 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pasithea Therapeutics in a research note on Monday, December 29th. Finally, HC Wainwright began coverage on shares of Pasithea Therapeutics in a report on Monday, December 8th. They issued a “buy” rating and a $3.00 target price on the stock. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $3.00.

View Our Latest Stock Report on Pasithea Therapeutics

Insider Buying and Selling at Pasithea Therapeutics

In other Pasithea Therapeutics news, Director Lawrence Steinman acquired 133,333 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were acquired at an average price of $0.75 per share, with a total value of $99,999.75. Following the completion of the transaction, the director directly owned 199,691 shares in the company, valued at $149,768.25. This trade represents a 200.93% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have purchased 199,999 shares of company stock worth $149,999. 2.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Pasithea Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC lifted its stake in shares of Pasithea Therapeutics by 43.7% in the third quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock worth $48,000 after acquiring an additional 20,483 shares during the period. Two Sigma Investments LP bought a new position in Pasithea Therapeutics during the 3rd quarter worth approximately $26,000. Finally, AdvisorShares Investments LLC lifted its position in shares of Pasithea Therapeutics by 33.1% in the 3rd quarter. AdvisorShares Investments LLC now owns 257,696 shares of the company’s stock worth $186,000 after purchasing an additional 64,149 shares during the period. Institutional investors and hedge funds own 23.92% of the company’s stock.

About Pasithea Therapeutics

(Get Free Report)

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.